AI-powered multiomic platform honored for driving discovery, patient stratification and clinical trial optimization

BostonGene, a leader in AI-powered solutions for drug discovery and development, has won Platinum in the AI Research Innovation category at the 2025 Pinnacle Awards. This recognition underscores BostonGene’s pivotal role in transforming multiomic data into actionable insights that drive smarter trial design, enable patient stratification and accelerate development timeliness--helping bring therapies to patients faster.

“We’re proud to receive this award, which highlights the impact of our platform in advancing therapeutic development,” said Alexander Bagaev, PhD, Chief Product Officer at BostonGene. “By integrating AI, multiomic profiling and real-world evidence, we enable drug developers to make smarter decisions—identifying responder populations, de-risking pipelines and shortening trial timelines. The result is a faster path to life-changing treatments for patients.”

AI-Powered Innovation Driving Therapeutic Success

BostonGene’s platform integrates genomic, transcriptomic, immune and spatial profiling—including whole exome and transcriptome sequencing, liquid biopsy, flow cytometry and spatial proteomics—delivering a comprehensive, multidimensional view of disease biology.

With this integrated view, the platform enables:

• Discovering predictive biomarkers to guide precision trial design
• Improving patient stratification to increase response rates
• Assessing adverse event risk to strengthen safety
• Optimizing trial endpoints and inclusion criteria to accelerate development

Breaking Through Traditional Limitations

Unlike conventional approaches that rely on static, single-gene markers, BostonGene’s proprietary AI models—trained on large-scale, real-world datasets—capture the full complexity of the tumor and immune microenvironment.

These models enable:

• Predicting treatment response with greater accuracy
• Identifying resistance mechanisms earlier
• Reducing late-stage clinical trial failures

By providing decision-ready evidence from discovery through pivotal trials, BostonGene empowers drug developers to optimize trial design, prioritize assets with confidence, minimize R&D risk and accelerate commercialization.

The Pinnacle Awards celebrate innovation and excellence in technology across industries. Judged by a panel of industry experts, the program honors organizations delivering measurable impact through breakthrough solutions that set new standards in their fields.

About BostonGene Corporation

BostonGene helps drug developers de-risk and accelerate research and development using a clinically validated AI platform purpose-built for oncology and supported by a CLIA-certified and CAP-accredited clinical laboratory. By integrating advanced molecular and immune profiling with clinical data, we uncover actionable insights that inform trial design, optimize patient selection and improve clinical outcomes. Our diagnostic and treatment recommendation solutions are used in clinical settings to personalize care and guide therapy decisions for patients. For more information, visit www.BostonGene.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250917320898/en/

By integrating AI, multiomic profiling and real-world evidence, we enable drug developers to make smarter decisions—identifying responder populations, de-risking pipelines and shortening trial timelines.